openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings
WARNINGS Cardiovascular Disease Cevimeline can potentially alter cardiac conduction and/or heart rate. Patients with significant cardiovascular disease may potentially be unable to compensate for transient changes in hemodynamics or rhythm induced by cevimeline. Cevimeline should be used with caution and under close medical supervision in patients with a history of cardiovascular disease evidenced by angina pectoris or myocardial infarction. Pulmonary Disease Cevimeline can potentially increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Cevimeline should be administered with caution and with close medical supervision to patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease. Ocular Ophthalmic formulations of muscarinic agonists have been reported to cause visual blurring which may result in decreased visual acuity, especially at night and in patients with central lens changes, and to cause impairment of depth perception. Caution should be advised while driving at night or performing hazardous activities in reduced lighting.
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Cevimeline was administered to 1777 patients during clinical trials worldwide, including Sjögren’s patients and patients with other conditions. In placebo-controlled Sjögren’s studies in the U.S., 320 patients received cevimeline doses ranging from 15 mg tid to 60 mg tid, of whom 93% were women and 7% were men. Demographic distribution was 90% Caucasian, 5% Hispanic, 3% Black and 2% of other origin. In these studies, 14.6% of patients discontinued treatment with cevimeline due to adverse events. The following adverse events associated with muscarinic agonism were observed in the clinical trials of cevimeline in Sjögren’s syndrome patients: Table 1 Adverse Event Cevimeline 30 mg (tid) (N N is the total number of patients exposed to the dose at any time during the study. =533) Placebo (tid) (N=164) Excessive Sweating 18.7% 2.4% Nausea 13.8% 7.9% Rhinitis 11.2% 5.4% Diarrhea 10.3% 10.3% Excessive Salivation 2.2% 0.6% Urinary Frequency 0.9% 1.8% Asthenia 0.5% 0% Flushing 0.3% 0.6% Polyuria 0.1% 0.6% In addition, the following adverse events (≥3% incidence) were reported in the Sjögren’s clinical trials: Table 2 Adverse Event Cevimeline 30 mg (tid) (N N is the total number of patients exposed to the dose at any time during the study. =533) Placebo (tid) (N=164) Headache 14.4% 20.1% Sinusitis 12.3% 10.9% Upper Respiratory Tract Infection 11.4% 9.1% Dyspepsia 7.8% 8.5% Abdominal Pain 7.6% 6.7% Urinary Tract Infection 6.1% 3% Coughing 6.1% 3% Pharyngitis 5.2% 5.4% Vomiting 4.6% 2.4% Injury 4.5% 2.4% Back Pain 4.5% 4.2% Rash 4.3% 6% Conjunctivitis 4.3% 3.6% Dizziness 4.1% 7.3% Bronchitis 4.1% 1.2% Arthralgia 3.7% 1.8% Surgical Intervention 3.3% 3% Fatigue 3.3% 1.2% Pain 3.3% 3.0% Skeletal Pain 2.8% 1.8% Insomnia 2.4% 1.2% Hot Flushes 2.4% 0% Rigors 1.3% 1.2% Anxiety 1.3% 1.2% The following events were reported in Sjögren’s patients at incidences of
adverse reactions table
Table 1Adverse EventCevimeline 30 mg (tid) (NN is the total number of patients exposed to the dose at any time during the study.=533)Placebo (tid) (N=164)Excessive Sweating18.7%2.4%Nausea13.8%7.9%Rhinitis11.2%5.4%Diarrhea10.3%10.3%Excessive Salivation2.2%0.6%Urinary Frequency0.9%1.8%Asthenia0.5%0%Flushing0.3%0.6%Polyuria0.1%0.6%